Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

The FDA is allowing pharmacies to dispense compounded versions of semaglutide and tirzepatide ... of the weight loss drugs — large amounts of people qualify for them and their high cost ...

The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...

Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

As certain weight-loss drugs have become increasingly popular, scammers are taking notice and coming out of the woodwork to ...